QuantuMDx Wins Made in North East Medical Life Sciences Award 2022

QuantuMDx team at North East Medical Life Science Awards

NEWCASTLE UPON TYNE, UK, 25 MARCH 2022. QuantuMDx Group Limited (“QuantuMDx”), is pleased to announce that it has won the Medical Life Sciences award at the Made in North East Awards 2022. The Made in North East Awards applaud quality products and services that manufacturing and engineering companies supply and the skilled people that work for them.  

Jonathan O’Halloran, Chief Executive, QuantuMDx, said: “We are very proud of this achievement, and I am thankful to our team for all their hard work, developing award-winning tech under the challenging backdrop of COVID-19.”

“This award further validates the high-quality technology we are developing at QuantuMDx and comes at an exciting time for the Company following the recent CTDA approval of our Q-POC™ SARS-CoV-2 assay and as we continue to expand the menu of tests for Q-POC™ adding a multiplex respiratory panel and sexually transmitted infections, amongst others.”

Notes to editor:

About QuantuMDx:

QuantuMDx is a progressive MedTech company passionate about empowering the world to control disease and reduce suffering. QuantuMDx solves real-world diagnostic problems by creating multiplex molecular solutions for the Point of Need, for anyone, anywhere.

QuantuMDx has global operations and strategic partnerships – keeping it at the forefront of molecular diagnostics. 

Q-POC™ is a rapid, simple to use, portable, sample to answer PCR device and has been designed for use in a wide range of settings, such as hospitals, clinics, pharmacies, and workplace testing providing accurate PCR results at the Point of Need. Q-POC™ and its first test, a SARS-CoV-2 multiplex detection assay, are CE-IVD marked under the In Vitro Diagnostics Directive (98/79/EC), enabling use within Europe. It tests multiple targets of the disease for a future proof COVID-19 testing solution at the Point of Need. 

QuantuMDx plans to launch a range of syndromic multiplex testing assays over the coming months and years. 

For more information about QuantuMDx and Q-POC™, its rapid PCR point of care system, go to: www.quantumdx.com

For media enquiries and interview requests:

Emma Long, Marketing Communications Manager, QuantuMDx,
M: +44 (0) 7495 341 930  T: +44 (0) 870 803 1234  / emma.long@quantumdx.com

Chris Gardner, Matthew Neal and Lindsey Neville, Consilium Strategic Communications, +44 (0)20 3709 5700 / quantumdx@consilium-comms.com

For investor enquiries:

David Wilson, Nigel Barnes and Jeff Glushakow, WG Partners (Financial Adviser to QuantuMDx), +44 (0)20 3705 9330 / quantumdx@wgpartners.co.uk

Image gallery

Q-POC system from QuantuMDx
Q-POC system from QuantuMDx - Close view